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Abstract
Background: Keratinocyte growth factor receptor (KGFR) is a splice variant of the FGFR2 gene expressed in epithelial cells.
Activation of KGFR is a key factor in the regulation of physiological processes in epithelial cells such as proliferation,
differentiation and wound healing. Alterations of KGFR signaling have been linked to the pathogenesis of different epithelial
tumors. It has been also hypothesized that its specific ligand, KGF, might contribute to the development of resistance to 5-
fluorouracil (5-FU) in epithelial cancers and tamoxifen in estrogen-positive breast cancers.
Methodology/Principal Findings: Small interfering RNA was transfected into a human keratinocyte cell line (HaCaT), a
breast cancer derived cell line (MCF-7) and a keratinocyte primary culture (KCs) to induce selective downregulation of KGFR
expression. A strong and highly specific reduction of KGFR expression was observed at both RNA (reduction=75.7%,
P=0.009) and protein level. KGFR silenced cells showed a reduced responsiveness to KGF treatment as assessed by
measuring proliferation rate (14.2% versus 39.0% of the control cells, P,0.001) and cell migration (24.6% versus 96.4% of
the control cells, P=0.009). In mock-transfected MCF-7 cells, KGF counteracts the capacity of 5-FU to inhibit cell
proliferation, whereas in KGFR silenced cells KGF weakly interferes with 5-FU antiproliferative effect (11.2% versus 28.4% of
the control cells, P=0.002). The capacity of 5-FU to induce cell death is abrogated by co-treatment with KGF, whereas in
KGFR silenced cells 5-FU efficiently induces cell death even combined to KGF, as determined by evaluating cell viability.
Similarly, the capacity of tamoxifen to inhibit MCF-7 and KCs proliferation is highly reduced by KGF treatment and is
completely restored in KGFR silenced cells (12.3% versus 45.5% of the control cells, P,0.001).
Conclusions/Significance: These findings suggest that selective inhibition of the KGF/KGFR pathway may provide a useful
tool to ameliorate the efficacy of the therapeutic strategies for certain epithelial tumors.
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Introduction
Keratinocyte growth factor receptor (KGFR/FGFR2-IIIb) is a
tyrosine kinase protein that belongs to the family of the fibroblast
growth factor receptors (FGFRs). KGFR represents a splicing
transcript variant of FGFR2 gene and is expressed on epithelial
cells of different organs. The alternatively spliced isoform, known
as FGFR2-IIIc, is found in cells of mesenchymal lineages [1,2].
KGFR plays a key role in the control of epithelial growth and
differentiation, carrying out its biological effects in a paracrine way
[3] through high affinity binding to its specific ligands, namely
keratinocyte growth factor (KGF/FGF7), FGF10 and FGF22 [4].
Among them, KGF acts not only as a potent mitogen for primary
human keratinocytes, but also promoting their differentiation
program [5] and protecting them against apoptosis induction
[6,7]. Furthermore, KGF is involved in both experimental [8,9]
and in vivo [10] wound healing models, stimulating migration of
keratinocytes [11,12] and inducing reorganization of actin
cytoskeleton, therefore increasing epithelial cell motility [13].
Recently, there has been growing interest about the potential
role of alterations of KGF/KGFR signaling in epithelial
tumorigenesis. Increased KGFR mRNA expression has been
detected in a wide range of tumors of epithelial origin, such as
lung, colon, gastric, pancreas and prostate cancers. In some cases,
such increased expression seems to be associated with cell
transformation and, perhaps, malignant progression [14]. More-
over, KGF administration has been shown to increase cell motility
in estrogen receptor (ER)-positive breast tumor cells [15,16], to be
potentially involved in breast cancer progression and metastasis
[17] and to enhance the invasive potential of gastric carcinoma
derived cell lines overexpressing KGFR [18].
Other studies led to hypothesize that KGF may exert
antiapoptotic activity on certain cancer cells as well as inhibition
of apoptosis induced by the chemotherapeutic drug 5-fluorouracil
PLoS ONE | www.plosone.org 1 June 2008 | Volume 3 | Issue 6 | e2528(5-FU) [19–22]. The development by cancer cells of resistance to
traditional chemotherapeutic agents, such as 5-FU, is frequently
observed and remains a major obstacle to a successful treatment of
cancer and a prominent cause of tumor recurrence after
chemotherapy [23].
Furthermore, it has been suggested that alterations of the
pathways involving FGFs and cognate receptors might represent
one of the mechanisms of resistance to tamoxifen that finally
develops in many ER-positive breast cancers [24–27]. However,
this hypothesis is not completely ascertained and the specific role
played by the large family of the FGFs is far from being
understood.
The approach based on selective downregulation of proteins
involved in cellular processes correlated to tumor progression
represents a promising frontier for cancer treatment. Transfection
of specific small interfering RNAs (siRNAs) is a powerful tool to
achieve a gene-specific knockdown and represents a potent
therapeutic strategy for the treatment of several diseases, such as
viral infections, neurological disorders and cancers [28].
The exclusive target specificity of siRNA against disease-
relevant mRNAs is an essential prerequisite for utilization of this
technology. In this study, we selectively downregulated KGFR
mRNA and protein expression in three epithelial cell lines,
HaCaT keratinocytes, MCF-7 breast cancer cell and primary
cultured keratinocytes (KCs), by a new approach of siRNA design,
based on the utilization of DICER endonuclease substrate 27-mer
dsRNAs to trigger RNA interference (RNAi). This technique
provides enhanced efficacy and longer duration of RNAi as
compared to traditional 21-mer siRNAs, allowing usage of lower
concentrations of RNAi in target cells, which greatly reduces the
side effects. Furthermore, it allows the targeting of sites that are
refractory to suppression with 21-mer siRNAs [29].
We analyzed the effects of KGFR siRNA on characteristics bio-
parameters such as cell viability, proliferation, apoptosis and
migration of the tested cell lines. Finally, we evaluated whether the
downregulation of KGFR expression is able to inhibit 5-FU and
tamoxifen resistance induced by KGF in cell cultures.
Results
Inhibition of KGFR mRNA expression by siRNAs
There are no clear rules governing siRNA target site selection for
specific mRNA sequences. However, within a single mRNA
sequence different siRNA molecules show a dramatic variability
in terms of efficacy and specificity of gene silencing. Here we used
laboratory- and web-based programs, according to the previously
described criteria (http://www.rockefeller.edu/labheads/tuschl/
sirna.html), to select three siRNAs sequences directed against the
FGFR2 gene. It is known that the same gene codes for two
alternative transcripts, designated as KGFR/FGFR2-IIIb and
FGFR2-IIIc, that differ for a divergent stretch of 49 amino acids
in their extracellular domain and display different ligand-binding
characteristics. Thus, to realize a specific knockdown of the KGFR
transcript, we selected siRNAs sequences targeted within the exon 8
of FGFR2 gene, which is spliced only in the KGFR isoform
(Fig. 1A). All the siRNAs sequences were entered into a BLAST
search to ensure that there was no significant homology with other
genes. As concerning the relative expression of the two FGFR2
isoforms in our experimental models, HaCaT cells have been
previously shown to express the FGFR2-IIIc variant of FGFR2 in
two orders of magnitude lesser amount than the FGFR2-IIIb splice
variant [30]; in MCF-7 cells, previously shown to express both
isoforms [31], we demonstrated that the FGFR2-IIIb expression is
greatly higher than that of FGFR2-IIIc (11 fold increase) (Fig. 1B).
The ability of each designed siRNA and of a pooled set of the three
duplexes to specifically reduce the levels of KGFR mRNA, without
affecting the expression of the FGFR2-IIIc isoform, was assayed in
MCF-7 and HaCaT cells. Transient transfections were used to
deliver each siRNA and cells incubated with the liposomal vector
alone (mock transfection) were used as control. The optimal
concentration for siRNA transfection was experimentally deter-
mined to be 5 nM (data not shown), in keeping with recent
observations that indicated toxic mechanisms, off-target effects and
stimulation of immune response induced by high doses of synthetic
RNAi in vitro and in vivo [32]. The ability of the various siRNAs to
reducethe amount ofKGFRmRNAwasestimatedbyQ-RT-PCR.
In MCF-7 cells we also evaluated the specificity of the designed
siRNAs. KGFR and FGFR2-IIIc mRNA levels were normalized to
the b-actin mRNA levels. 48 h after transfection, MCF-7 cells
transfected with the pooled set of siRNA-1, -2 and -3 expressed a
statistically significant reduced amount of KGFR mRNA compared
to the mock-transfected cells (0.243 fold, reduction=75.7%,
P=0.009) (Fig. 2A). A less evident effect was obtained by
transfection with the individual duplexes: siRNA-1 (0.613 fold,
reduction=38.7%, P=0.168), siRNA-2 (0.405 fold, reduc-
tion=59.5%, P=0.068) and siRNA-3 (0.406 fold, reduc-
tion=59.4%, P=0.061) (Fig. 2A). Conversely, neither individual
siRNAs nor the siRNA-pool showed any inhibitory effect on
FGFR2-IIIc mRNA levels (siRNA-1: 0.902 fold, reduction=9.8%,
P=0.71; siRNA-3: 0.914 fold, reduction=8.6%, P=0.36; si-RNA-
3: 0.943 fold, reduction=5.7%, P=0.52; siRNA-pool: 1.028 fold,
difference=2.8%, P=0.85) (Fig. 2B).
Therefore, all the subsequent experiments were carried out by
transfecting the siRNA-pool, which matches the commonly
adopted criteria of siRNA efficiency (.70% reduction in target
mRNA). Furthermore, since the pool shows a high specificity for
KGFR isoform, it will be referred as siKGFR in the rest of the
manuscript.
Time course of siRNA-mediated KGFR silencing
To evaluate the duration and efficacy of KGFR silencing, we
performed time course experiments on HaCaT cells transfected
with siKGFR, determining the amount of KGFR mRNA by Q-
RT-PCR at 6, 24, 48, 72 and 96 h after transfection (Fig. 3A). A
reduction of KGFR mRNA expression was observed 24 h after
transfection, as compared to mock-transfected cells (1.127 versus
2.730 fold, difference=58.7%, P,0.001), while full efficacy was
achieved at 48 and 72 h (1.127 versus 4.779 fold, differ-
ence=76.4%, P,0.001 and 1.079 versus 4.463 fold, differ-
ence=75.8%, P,0.001, respectively) from transfection. 96 h after
transfection, a strong decrease in KGFR expression was observed
also in the control. However, in transfected cells, downregulation
of KGFR expression was still significant (1.215 versus 1.963 fold,
difference=38.1%, P=0.017). On the bases of the time course
results and according to previous reports showing that the peak of
KGFR protein expression is reached at 72 h after starvation [30]
we decided to perform all the subsequent experiments at 72 h
following siKGFR transfection.
Downregulation of KGFR mRNA and protein expression
by siRNA in KGF-treated HaCaT cells
It is known that treatment of epithelial cells with KGF induces
several events such as cell proliferation and differentiation through
binding to KGFR and internalization of the receptor coupled to
reduction of the level of KGFR mRNA expression. Thus, we
examined the effect of siKGFR transfection in cell cultures in
presence of 20 ng/ml KGF. mRNA and protein expression levels
were tested by Q-RT-PCR and Western blot analysis. A sharp
Effects of KGFR Silencing
PLoS ONE | www.plosone.org 2 June 2008 | Volume 3 | Issue 6 | e2528decrease of KGFR mRNA was observed in cells transfected with
siKGFR as compared to mock-transfected cells (0.232 fold,
reduction=76.8%, P=0.003) (Fig. 3B). In presence of KGF, we
observed a downmodulation in the expression of KGFR also in
mock-transfected cells. However, KGFR mRNA inhibition by
siRNA was still evident (0.265 versus 0.598 fold, reduc-
tion=55.7%, P=0.018) (Fig. 3B). In the same set of experiments,
the levels of KGFR protein expression were also assayed by
Western blot. As shown in Fig. 3C, KGFR expression was
significantly decreased in siKGFR-transfected cells as compared to
mock-transfected cells. Densitometric analysis confirmed that
siKGFR reduced protein expression, in both untreated and
KGF-treated cells, by more than 50% with respect to mock-
transfected cells (0.47 fold versus 1 fold, reduction=53% and 0.20
versus 0.73 fold, reduction=72.6%, respectively) (Graph Fig. 3C).
siRNA-mediated downregulation of KGFR inhibits cell
proliferation and cell migration induced by KGF
To evaluate the biological effects of KGFR silencing, we
examined the siKGFR capacity to affect the KGF-induced
proliferation by carrying out a proliferation assay on the HaCaT
cell line. Plated cells were transfected with siKGFR and grown for
48 h in standard medium supplemented or not with 20 ng/ml
KGF. Cell proliferation was determined by counting cells positive
for Ki67 antigen, which identifies cycling cells, and reported in
graph as percentage of positive cells (Fig. 4A). As expected, in
mock-transfected cells we observed an increase in HaCaT cells
proliferation after KGF treatment, as compared to untreated cells
(39% versus 13.6%, 2.9 fold increase, P,0.001). The downreg-
ulation of KGFR expression through specific siRNA almost
completely abolished KGF effect on HaCaT cells proliferation,
Figure 1. KGFR and FGFR2-IIIc mRNA relative expression levels in MCF-7 cells. (A) Schematic drawing representing the alternative splicing
of FGFR2-IIIc and KGFR/FGFR2-IIIb. The inset (*) reports the cDNA sequence (nucleotides from 1590 to 1698) corresponding to the whole exon 8, with
the sequences targeted by the three siRNAs (grey boxes). (B) The levels of KGFR and FGFR2-IIIc mRNA expression were determined by Q-RT-PCR, and
normalized to b-actin mRNA levels. KGFR mRNA in MCF-7 cells was determined as fold with respect to FGFR2-IIIc mRNA. The graph show the
interquartile range of three independent experiments (boxes), their mean (horizontal dotted bars) and 95% Confidence Interval (CI) (whiskers). Two-
sided Student’s t test was used to compare KGFR versus FGFR2-IIIc expression: * P,0.001. The accompanying table reports mean expression level,
Standard Error (S.E.), and 95% CI for each assayed sample.
doi:10.1371/journal.pone.0002528.g001
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2.7 fold difference, P,0.001) (Graph Fig. 4A).
We then analyzed the impact of KGFR silencing on cell
migration, another complex and strictly regulated cellular process
strongly induced by KGF treatment. To this end, we performed a
wound-healing assay. 48 h after transfection with siKGFR a cell-
free area was introduced in monolayers of HaCaT cells, as
previously described [33]. Cells treated or not with 50 ng/ml
KGF, the concentration reported to be more efficient in this assay
[34], were allowed to migrate from the edge of the wound for 24 h.
As shown in Fig. 4B, the wound-closure was nearly completed 24 h
after initial wounding in KGF-treated mock-transfected cells, while
untreated mock-transfected cells showed a limited migration with
respect to T0 (96.4% versus 23.1%, 4.2 fold increase, P=0.035)
(Graph Fig. 4B). The transfection with siKGFR significantly
inhibited cell migration induced by KGF (Fig. 4B) and subsequently
reduced the recovered area from 96.4% of the control cells to
24.6%, 3.9 fold difference, P=0.009) (Graph Fig. 4B).
The same wound-healing assay was also performed on MCF-7
breast cancer cells, known to be responsive to KGF in terms of
motility [15], with similar results (Fig. 4C). KGF treatment
promoted a strong repopulation, as compared to that of untreated
mock-transfected cells (83% versus 29.6%, 2.8 fold increase,
P,0.001). In KGFR silenced cells, KGF-induced migration was
nearly abolished, in comparison to control cells (25.4% versus
83%, 3.3 fold difference, P,0.001) (Graph Fig. 4C).
These results suggested that KGFR silencing is effective in
inhibiting KGF biological effects, such as the stimulation of cell
proliferation and migration, either in HaCaT keratinocytes or
breast cancer epithelial cells.
KGFR silencing inhibits the restoration of cell
proliferation induced by KGF upon 5-FU stimulation
Frequently, cancer cells develop resistance to common chemo-
therapeutic drugs, such as 5-FU, thus challenging chemotherapy
efficacy [23]. In order to investigate the role of KGFR in the
establishment of resistance to 5-FU, we transiently knocked down
KGFR expression by siRNA in the MCF-7 breast cancer cell line.
The transfection with siKGFR was performed in the presence
or not of 20 ng/ml KGF, 25 mg/ml 5-FU or a combination of
Figure 2. Effect of three selected siRNAs on KGFR and FGFR2-IIIc mRNA expression levels. (A, B) MCF-7 cells were mock transfected or
transfected with 5 nM siRNA-1, -2, -3, or with a pooled set of them, and total RNA was extracted 48 h after transfection. The levels of KGFR (A) and
FGFR2-IIIc (B) mRNA expression were determined by Q-RT-PCR, and normalized to b-actin mRNA levels. KGFR (A) or FGFR2-IIIc (B) mRNA in siRNA-
transfected cells were determined as fold with respect to that expressed in mock-transfected cells. For each treatment, the graphs show the
interquartile range of three independent experiments (boxes), their mean (horizontal dotted bars) and 95% Confidence Interval (CI) (whiskers). Two-
sided Student’s t test was used to compare siKGFR-transfected versus mock-transfected cells: * P=0.009. The accompanying tables report mean
expression level, Standard Error (S.E.), and 95% CI for each assayed sample.
doi:10.1371/journal.pone.0002528.g002
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PLoS ONE | www.plosone.org 4 June 2008 | Volume 3 | Issue 6 | e2528Figure 3. Effect of siKGFR transfection on KGFR mRNA and protein expression levels. (A) HaCaT cells were mock transfected or
transfected with 5 nM siKGFR, and total RNA was extracted from the transfected cells 6, 24, 48, 72 and 96 h later. The levels of KGFR mRNA expression
were determined by Q-RT-PCR, and normalized to b-actin mRNA levels. The amount of KGFR mRNA at each time point was expressed as fold of KGFR
mRNA level with respect to the 6 h time point. For each time point, the graph shows the interquartile range of three independent experiments
(boxes), their mean (horizontal dotted bars) and 95% CI (whiskers). The accompanying table reports mean expression level, Standard Error (S.E.), and
95% CI for each assayed sample. Two-sided Student’s t test was used to compare siKGFR-transfected versus mock-transfected cells: * P,0.001 (24 h);
** P,0.001 (48 h); { P,0.001 (72 h); { P=0.017 (96 h). (B) HaCaT cells were mock transfected or transfected with 5 nM siKGFR. 24 h after transfection,
cells were treated with 20 ng/ml KGF for 48 h. The levels of KGFR mRNA expression were determined by Q-RT-PCR, and normalized to b-actin mRNA
levels. The amount of KGFR mRNA was expressed as fold of KGFR mRNA levels with respect to untreated mock-transfected cells. Graph and table
report the same sets of data as in (A) for each assayed sample. P values were determined using two-sided Student’s t test: * P=0.003 versus untreated
mock-transfected cells; ** P=0.018 versus KGF-treated mock-transfected cells. (C) HaCaT cells were transfected and treated as in (B), and the levels of
KGFR protein expression were determined by Western blot analysis using a polyclonal anti-bek antibody. The same blot was probed for tubulin as
control for equal loading. The amount of KGFR protein was evaluated by densitometric analysis; the values from a representative experiment were
standardized to tubulin levels, expressed as fold of KGFR protein with respect to untreated mock-transfected cells and reported as a graph.
doi:10.1371/journal.pone.0002528.g003
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PLoS ONE | www.plosone.org 5 June 2008 | Volume 3 | Issue 6 | e2528Figure 4. Effect of siKGFR transfection on KGF-induced proliferation and migration. (A) Proliferation assay. HaCaT cells, grown on
coverslips, were mock transfected or transfected with 5 nM siKGFR. 24 h after transfection, cells were treated with 20 ng/ml KGF for 48 h. Then, cells
were fixed and subjected to immunofluorescence analysis with a polyclonal antibody directed against Ki67 (red). The images are representative of
three independent experiments. Scale bar, 10 mm. Nuclei were visualized using 49, 6-diamido-2-phenylindole dihydrochloride (DAPI). The percentage
of Ki67-positive cells was determined by counting the number of Ki67-positive nuclei versus total number of nuclei in ten different areas randomly
taken from three different experiments, expressed as mean value695% CI and reported as a graph. P values were determined using the Student’s t
test: * P,0.001 versus untreated mock-transfected cells; ** P,0.001 versus KGF-treated mock-transfected cells. (B, C) Wound-healing assay. HaCaT
(B) and MCF-7 (C) cells were transfected as in (A). 48 h after transfection, a cell-free area (wound) was introduced in confluent cultures, as described
in Materials and Methods. Cells were treated or not with 50 ng/ml KGF and allowed to migrate for 24 h before photography under phase contrast
microscopy. The images are representative of three independent experiments. Scale bars, 10 mm. Cell migration was evaluated by repopulation of the
original wound with cells: the percentage of recovered area was measured by image analysis and values in the graphs are the average of three plates
for each condition695% CI. P values were determined using Student’s t test: (B)*P,0.001 versus untreated mock-transfected cells; ** P,0.001
versus KGF-treated mock-transfected cells. (C)*P=0.035 versus untreated mock-transfected cells; ** P=0.009 versus KGF-treated mock-transfected
cells.
doi:10.1371/journal.pone.0002528.g004
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analyzing both mRNA and protein expression levels.
As shown in Fig. 5A, treatment with KGF of mock-transfected
cells reduced the expression of KGFR mRNA compared to
untreated cells, independently from the presence of 5-FU in the
cell cultures (0.555 fold, reduction=44.5%, P=0.170, and 0.545
fold, reduction=45.5%, P=0.183, respectively). Moreover, 5-FU
alone poorly affected KGFR mRNA expression (0.911 fold,
reduction=8.9%, P=0.711). In siKGFR-transfected cultures, we
observed a strong effect on mRNA expression (0.133 fold,
reduction=86.7%, P=0.039), with modest variations in response
to the presence or absence of KGF and/or 5-FU. These data
confirmed that MCF-7 cells react similarly to HaCaT cells in
response to KGFR silencing. Furthermore, the results obtained at
RNA level were confirmed by analyzing protein expression, as
shown in Fig. 5B. The specific siRNA significantly decreased
KGFR protein in untreated cells, as well in KGF and/or 5-FU-
treated cells, by 60%–70% with respect to the same treatment in
mock-transfected cells (Graph Fig. 5B).
We next performed a proliferation assay on MCF-7 cells,
transfected with siKGFR or mock-transfected and grown for 48 h
in standard medium supplemented or not with KGF, 5-FU or a
combination of them, as above. Cell proliferation was evaluated by
counting cells positive for Ki67 antigen, and reported in graph as
percentage of positive cells (Fig. 6A). Also in MCF-7 we found an
increase in cell proliferation after KGF treatment, as compared to
untreated cells (34.8% versus 19.5%, 1.8 fold increase, P=0.004).
As expected, treatment with 5-FU revealed an antiproliferative
effect (6.0% versus 19.5%, 3.3 fold difference, P,0.001), which
was almost completely abrogated by co-treatment with KGF
(28.4% versus 6.0%, 4.7 fold difference, P,0.001). KGFR
downregulation by siRNA nearly abolished KGF proliferative
effect, both alone and in combination with 5-FU (15.7% versus
34.8%, 2.2 fold difference, P,0.001 and 11.2% versus 28.4%, 2.5
fold difference, P=0.002, respectively) (Fig. 6A).
It is known that ERK/MAPK pathway plays a major role in cell
proliferation and survival. Therefore, we performed a Western
blot analysis to assess ERK activation, by using antibodies either
specific for the phosphorylated form of the molecule or directed
against total ERK. As expected, in mock-transfected cells ERK
activation was significantly induced by KGF treatment (7.5 fold).
Conversely, 5-FU was able to decrease the levels of phosphory-
lated ERK (2.5 fold), which were almost completely restored by
the administration of KGF together with 5-FU (6.5 fold). In
siKGFR-transfected cells, according to the above results, the
stimulating effect of KGF on ERK phosphorylation was greatly
inhibited (2 fold) (Fig. 6B).
Furthermore, we assessed cell viability by crystal violet staining,
and its subsequent absorbance at 570 nm, which reflects
variations in cell number. 48 h after transfection, cells were
treated with KGF, 5-FU or a combination of them for 24 h, as
described above. Then, the remaining cells were fixed and
stained with 1% crystal violet (Fig. 7A). We compared the effect
of KGF and 5-FU on cell number, looking at the influence of
KGFR silencing in this process. In mock-transfected cells KGF
treatment was able to increase cell number (1.55 fold), 5-FU
induced a decrease of viable cells (0.45 fold), whereas in presence
of KGF, 5-FU was not effective (1.49 fold). On the other hand, in
siKGFR-transfected cells, 5-FU induced cell death as expected
(0.56 fold), whereas treatment with KGF was not able to induce
an increase of cell number (0.91 fold). In this case 5-FU keeps its
ability to determine cell death even in presence of KGF (0.49
fold) (Graph Fig. 7A).
In conclusion, these results highlight the ability of siKGFR to
counteract the capacity of KGF to block the antiproliferative effect
of chemotherapeutic agents, such as 5-FU.
Figure 5. Effect of siKGFR transfection on KGFR mRNA and
protein in cells treated with 5-FU. (A) MCF-7 cells were mock
transfected or transfected with 5 nM siKGFR. 48 h after transfection,
cells were treated with 20 ng/ml KGF, 25 mg/ml 5-FU or KGF plus 5-FU
for 24 h. The levels of KGFR mRNA expression were determined by Q-
RT-PCR, and normalized to b-actin mRNA levels. The amount of KGFR
mRNA in siKGFR-transfected cells was expressed as fold of the level of
KGFR mRNA with respect to untreated mock-transfected cells. For each
treatment, the graph shows the interquartile range of three indepen-
dent experiments (boxes), their mean (horizontal dotted bars), and 95%
CI (whiskers). The accompanying table reports mean expression level,
Standard Error (S.E.), and 95% CI for each assayed sample. P values were
determined using the Student’s t test: * P=0.039 versus untreated
mock-transfected cells. (B) MCF-7 cells were transfected and treated as
in (A), and the amount of KGFR protein was evaluated by Western blot
analysis with an anti-bek polyclonal antibody. Tubulin served as a
loading control. The amount of KGFR protein was evaluated by
densitometric analysis: the values from a representative experiment
were standardized to tubulin levels, expressed as fold of KGFR level with
respect to untreated mock-transfected cells and reported as a graph.
doi:10.1371/journal.pone.0002528.g005
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KGF upon 5-FU stimulation
Since cell treatment with 5-FU is known to induce apoptosis, we
assayed the protective role of KGF towards 5-FU induction of
apoptosis in MCF-7 cells [21,22]. MCF-7 cells were transfected
with siKGFR or mock-transfected and grown for 48 h in standard
medium supplemented or not with KGF, 5-FU or a combination
of them, as above. Cell apoptosis was evaluated by counting cells
positive for the cleaved, active form of caspase-3, a key executioner
of apoptosis, and reported in graph as percentage of positive cells
(Fig. 7B). KGF was able to induce a slight reduction in cell
apoptosis with respect to untreated cells (1.8% versus 3.1%, 1.7
fold difference, P=0.001), while the treatment with 5-FU caused a
strong apoptotic effect (16.9% versus 3.1%, 5.5 fold increase,
P=0.001). As previously demonstrated on the same cellular model
[21], the combination with KGF is able to protect MCF-7 cells
from apoptosis induced by 5-FU (3.0% versus 16.9%, 5.6 fold
difference, P,0.001). KGFR silencing suppressed KGF anti-
apoptotic effect, both alone and in combination with 5-FU (4.4%
versus 1.8%, 2.4 fold difference, P,0.001 and 15.1% versus 3.0%,
5.0 fold difference, P=0.001, respectively) (Fig. 7B).
These data were consistent with the results obtained by Q-RT-
PCR, Western blot analysis and proliferation assay, and showed
that knockdown of KGFR protein expression may be a
therapeutic approach to avoid KGF suppression of 5-FU-induced
apoptosis in cancer cells.
KGFR silencing restores the antiproliferative effect of
tamoxifen on ER positive cells
Tamoxifen is the most frequently prescribed anti-estrogen for
the management of estrogen-responsive human breast cancers.
Nevertheless, many tamoxifen responsive breast cancer patients
acquire tamoxifen resistance, which mechanisms are not com-
pletely understood [26]. A potential interaction with the FGF/
FGFR pathways has been hypothesized to be involved in this
process, although not yet clarified [27]. To assess the possible
contribution of KGF/KGFR to the establishment of tamoxifen
resistance, we analyzed the effects of KGF, 17b-estradiol (E2) and
tamoxifen treatment on MCF-7 cells. The transfection with
siKGFR was performed in the presence or not of 20 ng/ml KGF,
20 ng/ml E2, 100 nM tamoxifen or combinations of them. As
shown in Figure 8A–B, at RNA and protein level, respectively, in
mock-transfected cells KGF induced a decrease of KGFR
expression both with (0.631 fold, reduction=36.9%, P,0.001)
and without (0.735 fold, reduction=26.5%, P=0.049) co-
treatment with tamoxifen. Tamoxifen alone slightly affected
KGFR mRNA expression (1.113 fold, difference=11.3%,
P=0.032), while E2 caused an increase of more than two fold of
KGFR expression (2.062 fold, difference=106.2%, P,0.001),
which was not affected by co-treatment with tamoxifen (2.106 fold,
difference=110.6%, P,0.001). On the other hand, in siKGFR-
transfected cells a strong reduction of KGFR expression was
observed (0.126 fold, reduction=87.4%, P,0.001), and it was not
affected by treament with KGF, tamoxifen and E2 alone or in
combination.
The same cultures were subsequently assayed to determine
proliferation rates by counting cells positive for Ki67 antigen. Data
were reported in graph as percentage of positive cells (Fig. 8C). In
mock-transfected cells, we observed an increase in cell prolifera-
tion after KGF treatment, as compared to untreated cells (45%
versus 13.2%, 3.4 fold increase, P,0.001). As previously reported
[35,36], also E2 caused an induction of MCF-7 cells proliferation
(40.1% versus 13.2%, 3.0 fold increase, P=0.001). Tamoxifen
treatment induced only a slight reduction of basal proliferation
rate (12.1% versus 13.2%, 0.9 fold difference, P=0.065) that was
not altered by co-treatment with E2 (12.2% versus 12.1%,
P=0.787), while its effect was efficiently counteracted by KGF
(45.5% versus 12.1%, 3.8 fold increase, P,0.001). KGFR
silencing did not significantly affect E2-induced cell proliferation
(34.8% versus 40.1%, 1.2 fold difference, P=0.129), whereas in
silenced cells KGF was not able to stimulate cell proliferation both
Figure 6. Effect of siKGFR transfection on KGF-induced
inhibition of 5-FU antiproliferative activity. (A) MCF-7 cells,
grown on coverslips, were mock transfected or transfected with 5 nM
siKGFR and 48 h later they were treated or not with 20 ng/ml KGF,
25 mg/ml 5-FU or KGF plus 5-FU. After 24 h, cells were fixed and
subjected to immunofluorescence analysis with an anti-Ki67 polyclonal
antibody. Nuclei were visualized using 49, 6-diamido-2-phenylindole
dihydrochloride (DAPI). Cell proliferation was evaluated as percentage
of Ki67-positive nuclei versus total number of nuclei in ten different
areas randomly taken from three different experiments, expressed as
mean value695% CI and reported as a graph. P values were determined
using the Student’s t test: * P=0.004 and ** P,0.001 versus untreated
mock-transfected cells; *** P,0.001 versus 5-FU-treated mock-trans-
fected cells; { P,0.001 versus KGF-treated mock-transfected cells; {
P=0.002 versus KGF plus 5-FU-treated mock-transfected cells. (B) MCF-
7 cells were transfected and treated as in (A), and Western blot analysis
of the phosphorylation status of ERK was carried out using a phospho-
specific ERK monoclonal antibody (p-ERK). Levels of total ERK were
assessed by blotting with an ERK2-specific antibody. The amount of
activated ERK was evaluated by densitometric analysis: the values from
a representative experiment were standardized to total ERK levels,
expressed as fold of p-ERK expression with respect to untreated mock-
transfected cells and reported as a graph.
doi:10.1371/journal.pone.0002528.g006
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difference, P,0.001 and 12.3% versus 45.5%, 3.7 fold difference,
P,0.001, respectively).
The same set of experiments was then performed on primary
cultures of KCs (Fig. 9). Treatment with KGF, alone or in
combination with tamoxifen, barely reduced the expression of
KGFR mRNA compared to untreated cells, (0.722 fold,
reduction=27.8%, P=0.283, and 0.742 fold, reduction=25.8%,
P=0.134, respectively) and a decrease of KGFR mRNA
expression (0.544 fold, difference=45.6%, P=0.020) was also
observed in tamoxifen treated cells. Transfection with siKGFR
induced a significant decrease in KGFR expression (0.113 fold,
reduction=88.7%, P=0.002), with negligible variations due to
the presence of KGF, E2 and/or tamoxifen (Fig. 9A). As for the
proliferation rates, reported in Figure 9B, a strong increase was
observed in KGF as well as E2 treated cells (49.3% versus 13.9%,
3.5 fold increase, P,0.001 and 41.9% versus 13.9%, 3.0 fold
increase, P,0.001, respectively). Tamoxifen caused a decrease in
cell proliferation as compared to untreated cells (3.2% versus
13.9%, 4.3 fold difference, P,0.001) even in presence of E2 (3.6%
versus 3.2%, 1.1 fold difference, P=0.756). However, tamoxifen
effect was abolished by KGF-induced cell growth in co-treated
cultures (40.5% versus 3.2%, 12.6 fold increase, P,0.001). In
KGFR silenced KCs, a strong reduction of the capacity of KGF to
induce cell proliferation was observed (16.2% versus 15%, 1.1 fold
increase, P=0.762). Even in this case, E2 capacity is only partially
affected (34.1% versus 41.9%, 1.2 fold difference, P,0.001).
However, in silenced cells tamoxifen blockade of cell proliferation
was not counteracted by KGF (10.5% versus 40.5%, 3.9 fold
difference, P,0.001)
Figure 7. Effect of siKGFR transfection on cell viability and KGF-induced inhibition of 5-FU proapoptotic activity. (A) MCF-7 cells were
mock transfected or transfected with 5 nM siKGFR and 48 h later they were treated or not with 20 ng/ml KGF, 25 mg/ml 5-FU or KGF plus 5-FU. After
24 h, cells were fixed, stained with 1% crystal violet and analyzed at an absorbance of 570 nm. The values from a representative experiment were
expressed as relative optical density and reported as a graph. (B) MCF-7 cells, grown on coverslips, were transfected and treated as in (A). After 24 h,
they were fixed and subjected to immunofluorescence analysis with an antibody directed against the cleaved form of caspase-3. Nuclei were
visualized using 49, 6-diamido-2-phenylindole dihydrochloride (DAPI). The percentage of apoptotic cells was evaluated by counting the number of
cleaved caspase-3 positive nuclei versus total number of nuclei in ten different areas randomly taken from three different experiments, expressed as
mean value695% CI and reported as a graph. P values were determined using the Student’s t test: * P=0.001 and ** P=0.001 versus untreated mock-
transfected cells; *** P,0.001 versus 5-FU-treated mock-transfected cells; { P,0.001 versus KGF-treated mock-transfected cells; { P=0.001 versus KGF
plus 5-FU-treated mock-transfected cells.
doi:10.1371/journal.pone.0002528.g007
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PLoS ONE | www.plosone.org 9 June 2008 | Volume 3 | Issue 6 | e2528Figure 8. Effect of siKGFR transfection on KGF-induced inhibition of Tamoxifen antiproliferative activity in MCF-7 cells. (A) MCF-7
cells were mock transfected or transfected with 5 nM siKGFR. 48 h after transfection, cells were treated with 20 ng/ml KGF, 20 ng/ml E2, 100 nM
tamoxifen (Tam), KGF plus Tam or E2 plus Tam for 24 h. The levels of KGFR mRNA expression were determined by Q-RT-PCR, and normalized to b-
actin mRNA levels. The amount of KGFR mRNA in siKGFR-transfected cells was expressed as fold of the level of KGFR mRNA with respect to untreated
mock-transfected cells. For each treatment, the graph shows the interquartile range of three independent experiments (boxes), their mean
(horizontal dotted bars), and 95% CI (whiskers). The accompanying table reports mean expression level, Standard Error (S.E.), and 95% CI for each
assayed sample. P values were determined using the Student’s t test: * P,0.001 versus untreated mock-transfected cells. (B) MCF-7 cells were
transfected and treated as in (A), and the amount of KGFR protein was evaluated by Western blot analysis with an anti-bek polyclonal antibody.
Tubulin served as a loading control. (C) MCF-7 cells, grown on coverslips, were transfected and treated as in (A). After 24 h, cells were fixed and
subjected to immunofluorescence analysis with an anti-Ki67 polyclonal antibody. Nuclei were visualized using 49, 6-diamido-2-phenylindole
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PLoS ONE | www.plosone.org 10 June 2008 | Volume 3 | Issue 6 | e2528dihydrochloride (DAPI). Cell proliferation was evaluated as percentage of Ki67-positive nuclei versus total number of nuclei in ten different areas
randomly taken from three different experiments, expressed as mean value695% CI and reported as a graph. P values were determined using the
Student’s t test: * P,0.001 and ** P=0.001 versus untreated mock-transfected cells; *** P,0.001 versus Tam-treated mock-transfected cells;
{ P,0.001 versus KGF-treated mock-transfected cells; { P,0.001 versus KGF plus Tam-treated mock-transfected cells.
doi:10.1371/journal.pone.0002528.g008
Figure 9. Effect of siKGFR transfection on KGF-induced inhibition of Tamoxifen antiproliferative activity in KCs cells. (A) KCs cells
were mock transfected or transfected with 5 nM siKGFR. 48 h after transfection, cells were treated with 20 ng/ml KGF, 20 ng/ml E2, 100 nM Tam, KGF
plus Tam or E2 plus Tam for 24 h. The levels of KGFR mRNA expression were determined by Q-RT-PCR, and normalized to b-actin mRNA levels. The
amount of KGFR mRNA in siKGFR-transfected cells was expressed as fold of the level of KGFR mRNA with respect to untreated mock-transfected cells.
For each treatment, the graph shows the interquartile range of three independent experiments (boxes), their mean (horizontal dotted bars), and 95%
CI (whiskers). The accompanying table reports mean expression level, Standard Error (S.E.), and 95% CI for each assayed sample. P values were
determined using the Student’s t test: * P=0.002 versus untreated mock-transfected cells. (B) KCs cells, grown on coverslips, were transfected and
treated as in (A). After 24 h, cells were fixed and subjected to immunofluorescence analysis with an anti-Ki67 polyclonal antibody. Nuclei were
visualized using 49, 6-diamido-2-phenylindole dihydrochloride (DAPI). Cell proliferation was evaluated as percentage of Ki67-positive nuclei versus
total number of nuclei in ten different areas randomly taken from three different experiments, expressed as mean value695% CI and reported as a
graph. P values were determined using the Student’s t test: * P,0.001, ** P,0.001 and *** P,0.001 versus untreated mock-transfected cells;
1 P,0.001 versus Tam-treated mock-transfected cells; { P,0.001 versus KGF-treated mock-transfected cells; { P,0.001 versus E2- treated mock-
transfected cells; # P,0.001 versus KGF plus Tam-treated mock-transfected cells.
doi:10.1371/journal.pone.0002528.g009
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to prevent KGF from blocking the antiproliferative effect of
tamoxifen in ER positive cells.
Discussion
In the present study we took advantage of the mechanism of
RNAi to silence the expression of KGFR in epithelial cell lines.
Thus, we analyzed the effect of siKGFR on cell proliferation and
motility in transiently transfected cells. We also evaluated whether
downregulation of KGFR expression could restore the apoptotic
and antiproliferative effects of 5-FU and tamoxifen on a breast
cancer cell line as well as on epithelial primary cultures.
Alterations in the expression of growth factors and/or their high
affinity receptors have been shown to be involved in processes that
can lead to tumor development. The FGFR family and the related
ligands participate in the physiological processes that regulate
differentiation, proliferation, migration and cell survival [37].
Many splice variants generated from the 4 genes encoding the
FGFRs and 23 FGF ligands thus far identified yield a high number
of combinations ensuring a finely regulated cross-talk between
epithelial and mesenchymal cells. Moreover, proper FGFR
signaling requires restricted expression of specific receptors on
different cell types. Among FGFR, KGFR expression turned out
to be tissue specific, being expressed on epithelial cells under
physiological conditions [2].
Previous studies have reported that abnormal expression of
KGFR can be correlated with tumor progression, reduction of free
survival and worse prognosis in different epithelial cancers, such as
prostate, breast, gastric [38] and pancreatic [39] carcinomas. In
particular, in prostate cancer, lack of KGFR expression seems to
be associated to a more aggressive behavior of the tumor, which
becomes androgen-insensitive [40]. In salivary gland tumors, loss
of KGFR expression has been reported in malignant transforma-
tion [41]. On the other hand, in pancreatic cancer it has been
observed that co-expression of KGF and KGFR in tumor cells is
correlated with poorer prognosis. It has been hypothesized that
upregulation of either KGF or KGFR expression may contribute
to venous invasion, possibly through induction of VEGF-A
expression, thus causing a higher risk of metastasis [39]. In breast
cancer, KGFR upregulation has been documented in specimens
obtained at the early stages of tumors [42]. Thus, it has been
suggested that KGF-mediated stimulation of these cells might
contribute to the metastatic progression. KGF has been also
observed in some tumor cells of epithelial origin, despite its
physiologic expression is restricted to mesenchymal cells. This
finding has been documented in about a half of breast cancers and
a quarter of pancreatic adenocarcinomas, suggesting a potential
autocrine loop of the KGF/KGFR axis in these tumor cells
[21,43,44]. Co-expression of KGF and KGFR has been also
documented in the MCF-7 cell line. It has been suggested that co-
expression of KGF/KGFR in tumor cells might interfere with the
efficacy of some chemotherapeutic agents, thus contributing to a
poorer prognosis of the disease [21]. Furthermore, it has been
observed that KGF, following the binding to KGFR, exerts an
antiapoptotic role in epithelial cells, by affecting the regulation of
AKT/MAPK survival/proliferation pathway, whose end results
influence cell fate [45].
Moreover, acquired resistance to tamoxifen therapy in ER-
positive breast cancers is a frequent clinical observation, although
the mechanisms capable to determine this effect remain unclear.
Deregulations involving members of the FGF/FGFR family have
been suggested to play a role in this phenomenon [27].
In the present study we set up a system that efficiently reduces
KGFR expression in epithelial cells. At our knowledge, this is the
first highly specific RNAi active on KGFR without affecting the
closely related FGFR2-IIIc isoform. This finding might turn out
important to evaluate the effects on epithelial tumors characterized
by an altered activation of KGFR. Furthermore, it could represent
a useful approach to selectively study the pathway of KGFR
activation without interfering with other FGFR family members.
We observed that silencing of KGFR caused modifications in
the physiological behavior of the tested cell lines. Two major
effects of KGF treatment on epithelial cells were assayed. Both
proliferation rate, as measured by Ki67 marker, and migration
capacity, as determined by the in vitro wound-healing assay,
showed that KGFR silenced cells become poorly responsive to
KGF. These modifications of cell behavior are particularly
intriguing since high rates of proliferation and migration represent
two fundamental characteristics of malignant cells. It could be
envisioned the possibility that KGFR silencing in cancers,
particularly in those overexpressing KGFR and/or KGF, might
affect the growth rate of the primary tumor as well as its metastatic
potential.
A further interesting observation was obtained by evaluating the
effects of 5-FU in KGFR silenced cells. Previous researches have
shown that KGF interferes with the capacity of 5-FU to block cell
proliferation and to induce apoptosis [19,21]. We confirmed these
data in our study, but more importantly we observed that silencing
of KGFR expression restores the efficacy of 5-FU, as documented
by Ki67 labeling, index of cell proliferation, and by the viability
assay, measure of the capacity of 5-FU to cause cell death. These
results underline the potential role of the KGF/KGFR pathway in
decreasing the therapeutic efficacy of 5-FU treatment.
Similarly, in the breast cancer cell line MCF-7 and in epithelial
primary cultured cells, we observed that KGF treatment interferes
with the capacity of tamoxifen to block cell proliferation, whereas
KGFR silencing completely restores tamoxifen efficacy.
Although not clearly established, the involvement of the KGF/
KGFR pathway has been envisioned in different tumors of
epithelial origin. Recent data showing a possible association
between genetic alterations in the FGFR2 gene and risk of breast
cancers raised the interest to studies aimed to better address this
issue [46,47]. The altered expression of KGF/KGFR observed in
some cancers suggests that a screening to evaluate the expression
of KGFR and KGF in tumor biopsies might turn out useful as
prognostic marker. The present study, showing that silencing of
KGFR affects proliferation, motility and response of tumor-
derived cell lines to chemotherapeutic drugs, such as 5-FU and
tamoxifen, seems to indicate that KGFR may represent an
important target for the development of novel therapeutic
strategies.
Further studies are needed to prove specificity and efficacy of
siKGFR in vivo. Should these studies confirm our findings, it could
be envisioned the possibility that delivery of siRNAs within tumor
cells to downregulate KGFR expression might represent an
approach to overcome the reduced efficacy of drugs commonly
used in the treatment of tumors of epithelial origin, as well as to
reduce the rate of tumor growth and metastasis.
Materials and Methods
Cell culture and treatments
The estrogen receptor a-positive MCF-7 human breast
adenocarcinoma cell line, purchased from the American Type
Culture Collection (No. HTB-22, ATCC-LGC Promochem,
Teddington, UK), and the human keratinocyte cell line HaCaT
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(DMEM; Invitrogen, Karlsruhe, Germany), supplemented with
10% fetal bovine serum (FBS; Invitrogen) and antibiotics. Primary
cultures of human estrogen-sensitive keratinocytes (KCs) were
established from 1 cm
2 full-thickness mucosal biopsy of the vaginal
vestibule. Following enzymatic dissociation, keratinocytes were
seeded onto collagen IV (10 mg/ml)-coated culture plates and
maintained in chemical defined medium MCDB 153 (EpiLife,
Cascade Biologics, Inc., Portland, OR, USA), with medium
change twice a week, as previously reported [48].
For quantitative RT-PCR (Q-RT-PCR), Western blot analysis
and immunofluorescence, 20 h after transfection with siRNA
HaCaT cells were serum starved for 4 h and then treated for 48 h
with 20 ng/ml human recombinant KGF (Upstate Biotechnology,
Lake Placid, NY), while MCF-7 cells were treated with 20 ng/ml
KGF, 25 mg/ml 5-FU (Sigma-Aldrich, Milan, Italy) or a
combination of them. For wound-healing assay, 36 h after
transfection cells were serum starved for 12 h and then treated
for 24 h with 50 ng/ml KGF. For the experiments with 17b-
estradiol (E2) and tamoxifen, MCF-7 cells were grown in phenol
red-free DMEM supplemented with 10% dextran charcoal-treated
FBS (Invitrogen). Both MCF-7 and KCs were serum starved for
4 h and then treated for 48 h with 20 ng/ml KGF, 20 ng/ml E2
(Sigma-Aldrich), 100 nM tamoxifen or combinations of them.
Design and selection of siRNAs
The targeted sequences for human KGFR siRNAs, selected
from the cDNA sequence located ,0.2 kb after start codon, were
designed by using publicly available algorithms (www.ambion.
com/techlib/misc/siRNA_finder.html) and according to the
guidelines from Tuschl et al. [49]. In brief, we selected three 27-
mer RNA duplexes targeted to sequences located within the exon
8 of the FGFR2 gene, exclusively expressed in the KGFR/
FGFR2-IIIb isoform, and not in the FGFR2-IIIc. These duplexes,
named siRNA-1, siRNA-2 and siRNA-3, were analyzed by
BLAST (http://www.ncbi.nlm.nih.gov/BLAST) to ensure that
there were no significant sequence homologies with other genes.
Subsequently, they were synthesized by Invitrogen and dissolved
in the siRNAs buffer, as recommended by the manufacturer. The
efficacy of either the three individual duplexes or the pooled set of
them was assessed by Q-RT-PCR, the most efficient condition was
chosen for following studies and it was referred to as siKGFR.
In vitro transfection with siRNAs
HaCaT, MCF-7 and KCs cells were transfected with siRNAs
using the HiPerfect transfection reagent (Qiagen Inc., Hilden,
Germany), according to the manufacturer’s instructions. Briefly, 1
day prior to transfection cells were seeded at 1.5610
5 for HaCaT
or 2.0610
5 for MCF-7 and KCs per 60 mm Petri dish,
corresponding to a density of 60%-70% at the time of transfection.
The final optimal siRNA concentration was determined in 5 nM
(data not shown). Cells were incubated with HiPerfect alone
without siRNA as a negative control (mock transfection). Cells
were harvested 72 h after transfection for mRNA analysis, protein
expression, immunofluorescence and wound-healing assays. In
time course experiments, the analysis was performed 6, 24, 48, 72
and 96 h after transfection. In each case, three replicate
experiments were performed.
Quantitative RT-PCR
Cells were harvested and total RNA was extracted with the use
of TRIzol reagent (Invitrogen). cDNA was generated with
oligo(dT) from 1 mg of RNA using the SuperScript III Reverse
Transcriptase Kit (Invitrogen). After reverse transcription, the
abundance of KGFR or FGFR2-IIIc mRNA in HaCaT and
MCF-7 cells was quantified by Q-RT-PCR. Relative quantifica-
tion was performed using b-actin mRNA as an endogenous
control: for each examined sample, KGFR and FGFR2-IIIc
mRNA expression data were normalized to the b-actin expression.
The primers sets (Invitrogen) designed to detect each mRNA were
the following: KGFR forward, 59-ACTCGGGGATAAATAG-
TTCCAA-39; KGFR reverse, 59-CCTTACATATATATTCCC-
CAGCAT-39; FGFR2-IIIc forward, 59-CACCACGGACAAA-
GAGATTGA-39; FGFR2-IIIc reverse, 59- ATTACCCGC-
CAAGCACGTAT-39; b-actin forward, 59- CGCCGCCAG-
CTCACCATG-39; b-actin reverse, 59-CACGATGGAGGG-
GAAGACGG-39. TaqMan probes for KGFR (59-AAGTGCT-
GGCTCTGTTCAATGT-39), FGFR2-IIIc (59-TGTAACTTTT-
GAGGACGCTGGGGAA-39) and b-actin (59-TCGACAAC-
GGCTCCGGCATGTGCA-39) were purchased from MWG-
BIOTECH AG (Anzingerstr, Ebersberg, Germany). The Q-RT-
PCR reactions were performed using iQ Supermix (Bio-Rad
Laboratories, Hercules, CA) in a MyiQ
TM Thermal Cycle (Bio-
Rad), following the manufacturer’s instructions. For each sample
three replicates were performed. All reactions began with 3 min at
95uC for iTaq
TM DNA polymerase activation, followed by 40
cycles of 95uC for 15 sec for denaturation and 60uC for 1 min for
annealing-extension. Data were analyzed according to Pfaffl [50]
and were expressed as fold of KGFR or FGFR2-IIIc mRNA with
respect to control. For each graph, boxes indicated the
interquartile range, the horizontal dotted line indicated the mean
value and whiskers indicated 95% confidence intervals (CIs).
Western blot analysis
For Western blot analysis, siKGFR- and mock-transfected
HaCaT or MCF-7 cells, treated as above described, were lysed in
RIPA buffer. Total proteins (50–150 mg) were resolved under
reducing conditions by 8%–12% SDS–PAGE and transferred to
Immobilon-FL membranes (Millipore, Billerica, MA). For KGFR
detection, the membranes were incubated overnight at 4uC with
anti-bek,arabbitpolyclonalantibodyraisedagainsttheintracellular
domain of KGFR/FGFR2 (C-17; 1:200 dilution; Santa Cruz
Biotechnology, Santa Cruz, CA), followed by a goat anti-rabbit
horseradish peroxidase-conjugated secondary antibody (Sigma-
Aldrich). Bound antibody was detected by enhanced chemilumi-
nescence detection reagents (Pierce Biotechnology, Inc, Rockford,
IL), according to manufacturer’s instructions. To estimate the
protein equal loading, the membranes were rehydrated through
washing in TBS–T, stripped with 100 mM b-mercaptoethanol and
2% SDS for 30 min at 55uC and reprobed with an anti-tubulin
antibody (1:1000 dilution; Sigma-Aldrich). To detect MAPK
activation, membranes were incubated overnight at 4uC with a
monoclonal antibody that recognizes the phosphorylated form of
ERK (1:1000 dilution; Cell Signaling Technology, Danvers, MA),
followed by goat anti-mouse horseradish peroxidase-conjugated
secondary antibody (Sigma-Aldrich), which was visualized by
enhanced chemiluminescence. Protein equal loading was assessed
by reprobing the membranes with a polyclonal antibody directed
against ERK-2 (1:1000 dilution; Sigma-Aldrich). Densitometric
analysis was performed using Quantity One Program (Bio-Rad).
Briefly, the signal intensity for each band was calculated and the
background subtracted from experimental values. The resulting
values were then normalized, expressed as fold increase with respect
to the control value and visualized as graphs.
Immunofluorescence microscopy
Cells, grown on coverslips, were siKGFR- or mock-transfected
and treated as described above, then fixed in 4% paraformalde-
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followed by treatment with 0.1 M glycine in PBS for 20 min at
25uC and with 0.1% Triton X-100 in PBS for additional 5 min at
25uC to allow permeabilization. To assess cell proliferation, cells
were incubated with an anti-Ki67 rabbit polyclonal antibody (1:50
in PBS; Zymed Laboratories, San Francisco, CA), which identifies
cycling cells. The primary antibody was visualized using Texas
Red conjugated goat anti-rabbit IgG (1:100 in PBS; Jackson
ImmunoResearch Laboratories, West Grove, PA). To evaluate
apoptosis, cells were incubated with a primary antibody that
specifically detects the cleaved form of caspase-3 (1:400 in PBS;
Cell Signaling), visualized with a FITC-conjugated goat anti-
rabbit IgG (1:50 in PBS; Cappel Research Products, Durham,
NC). Nuclei were visualized using 49, 6-diamido-2-phenylindole
dihydrochloride (DAPI) (1:10000 in PBS; Sigma-Aldrich). Fluo-
rescence signals were analyzed by recording stained images using a
cooled CCD color digital camera SPOT-2 (Diagnostic Instru-
ments Incorporated, Sterling Heights, MI) and Axiovision software
(Carl Zeiss Inc., Oberkochen, Germany). The percentage of Ki67-
positive cells and of cleaved-caspase 3-positive cells was evaluated
by counting, for each treatment, a total of 500 cells, randomly
taken from ten microscopic fields in three different experiments,
expressed as mean value695% CI and reported as graphs.
Cell survival assay
To evaluate the cytotoxicity of 5-FU, siKGFR- or mock-
transfected MCF-7 cells were treated as described above, fixed for
10 min in a solution 10% acetic acid-10% methanol, stained with
crystal violet (1% w/v) and photographed using a Power Shot G5
digital camera (Canon, Inc., Tokyo, Japan). Since it is known that
the intensity of light passing through the crystal violet stained
culture is proportional to the number of cells per unit area [51], we
further measured the optical density of the stained cells at a
wavelength of 570 nm, and reported it as a graph.
Wound healing assay
HaCaT and MCF-7 cells were seeded at 2610
5 cells and
1.2610
5 cells per 35 mm Petri dish, respectively, transfected as
described above and grown until confluence. Confluent cells were
serum starved for 12 h and then a standardized cell-free area
(wound) was introduced by scraping the monolayer with a sterile
tip, as previously described [33]. After intensive wash, the
remaining cells were incubated for 24 h in the presence of
50 ng/ml KGF. Then, cells were fixed with 4% paraformaldehyde
for 30 min at 25uC and photographs were taken using an Axiovert
25 inverted microscope (Carl Zeiss) and a Power Shot G5 digital
camera (Canon, Inc.). Some plates were fixed and photographed
immediately after wounding, representing a T0 control. Migration
was quantified by a measure of the recovered wound area,
performed using the freely available image-processing software
ImageJ 1.38 (http://rsb.info.nih.gov/ij/). The data presented for
each cell line are a mean of triplicate experiments695% CI.
Statistical analysis
Data were analyzed by two-way analysis of variance (ANOVA)
and Student’s t test. 95% confidence intervals were calculated. All
statistical tests were two-sided, and P,0.05 were considered
statistically significant. Statistical analyses were performed using
STATA 8.0 (STATA Corporation, College Station, TX).
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